-
Novo Nordisk recently announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individu
-
Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years, while benefitting from a substantial decrease in risk of developing type 2 diabetes. In absolute terms, nearly 99% of individuals treated with tirzepatide remained diabetes-free at 176 weeks
-
Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A prespecified analysis from the SELECT trial H.M. Colhoun 1, S.E. Kahn2, P.M. Brown3, E.T.B. Olesen3, R. Bravo3, J. Deanfield4, A. Goudev5, G. Latkov
-
The 2024 Lasker~DeBakey Clinical Medical Research Award honors three scientists for their discovery and development of GLP-1-based drugs that have revolutionized the treatment of obesity. Joel Habener (Massachusetts General Hospital) and Svetlana Mojsov (The Rockefeller University) discerned the physiologically active form of the hormone, and Lotte Bjerre Knudsen (Novo Nordisk) turned it into medications that promote weight loss.
-
The new biosynthetic peptide development platform is an innovative platform based on advanced technologies and methods, aimed at accelerating the research and manufacturing process of peptide drugs. This platform combines technologies from the fields of biosynthesis,
